for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca's Lynparza reduces relapse and death in breast cancer patients

June 3 (Reuters) - AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in patients with breast cancer in a late stage trial, the British drugmaker said on Thursday. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up